SG10201702382RA - Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine - Google Patents

Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Info

Publication number
SG10201702382RA
SG10201702382RA SG10201702382RA SG10201702382RA SG10201702382RA SG 10201702382R A SG10201702382R A SG 10201702382RA SG 10201702382R A SG10201702382R A SG 10201702382RA SG 10201702382R A SG10201702382R A SG 10201702382RA SG 10201702382R A SG10201702382R A SG 10201702382RA
Authority
SG
Singapore
Prior art keywords
cyanoquinolines
capecitabine
anilino
antineoplastic combinations
antineoplastic
Prior art date
Application number
SG10201702382RA
Other languages
English (en)
Inventor
Kenneth Wang
Charles Zacharchuk
Florence Binlich
Susan Quinn
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201702382R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of SG10201702382RA publication Critical patent/SG10201702382RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201702382RA 2008-08-04 2009-08-04 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine SG10201702382RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8591308P 2008-08-04 2008-08-04
US17246609P 2009-04-24 2009-04-24

Publications (1)

Publication Number Publication Date
SG10201702382RA true SG10201702382RA (en) 2017-05-30

Family

ID=41226678

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201702382RA SG10201702382RA (en) 2008-08-04 2009-08-04 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
SG10202102855RA SG10202102855RA (en) 2008-08-04 2009-08-04 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202102855RA SG10202102855RA (en) 2008-08-04 2009-08-04 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Country Status (26)

Country Link
US (2) US8669273B2 (de)
EP (3) EP2326329B1 (de)
JP (1) JP5681108B2 (de)
KR (2) KR20140069340A (de)
CN (6) CN102202667A (de)
AU (1) AU2009279771B2 (de)
BR (1) BRPI0916694B1 (de)
CA (1) CA2730715C (de)
CY (1) CY1118602T1 (de)
DK (1) DK2326329T3 (de)
ES (2) ES2968373T3 (de)
HK (1) HK1218262A1 (de)
HR (1) HRP20170074T1 (de)
HU (1) HUE032958T2 (de)
IL (1) IL210616A (de)
LT (1) LT2326329T (de)
MX (1) MX2011001318A (de)
NZ (1) NZ590464A (de)
PL (2) PL2326329T3 (de)
PT (1) PT2326329T (de)
RU (1) RU2498804C2 (de)
SG (2) SG10201702382RA (de)
SI (1) SI2326329T1 (de)
SM (1) SMT201700084B (de)
WO (1) WO2010017163A1 (de)
ZA (1) ZA201101662B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20180128078A (ko) 2008-06-17 2018-11-30 와이어쓰 엘엘씨 Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물
NZ590464A (en) * 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
HUE061640T2 (hu) 2009-04-06 2023-07-28 Wyeth Llc Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
CN107441058A (zh) 2009-11-09 2017-12-08 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
RU2015152175A (ru) * 2013-06-19 2017-07-24 Ф. Хоффманн-Ля Рош Аг Комбинация ro5503781, капецитабина и оксалиплатина для терапии рака
TR201910701T4 (tr) * 2013-06-19 2019-08-21 Hoffmann La Roche Kanser terapisine yönelik ro5503781 ve kapesitabin kombinasyonu.
EP3097108B8 (de) 2014-01-23 2021-04-07 Immunolight, LLC Verwendung von psoralenderivaten und kombinationstherapie zur behandlung von zellproliferationsstörungen
WO2015123699A1 (en) 2014-02-17 2015-08-20 Children's National Medical Center Method and system for providing recommendation for optimal execution of surgical procedures
JP6458007B2 (ja) * 2014-04-04 2019-01-23 大鵬薬品工業株式会社 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
WO2017117474A1 (en) * 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
TW201827050A (zh) * 2017-01-22 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Egfr/her2抑制劑聯合嘧啶類抗代謝藥物的用途
CN111110681A (zh) * 2018-10-31 2020-05-08 正大天晴药业集团股份有限公司 喹啉衍生物联合卡培他滨在治疗肝癌的用途
WO2021104319A1 (zh) * 2019-11-25 2021-06-03 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐的联用药物组合物及其用途

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US865A (en) 1838-08-01 Improvement in fire-arms
US7399A (en) 1850-05-28 charles payne
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
TW254946B (de) 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
PL181304B1 (pl) 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EP1117659B1 (de) 1998-09-29 2003-12-03 Wyeth Holdings Corporation Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
KR20020071931A (ko) 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
PT1318837E (pt) 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
IL157898A0 (en) 2001-04-06 2004-03-28 Wyeth Corp Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
SG153647A1 (en) 2001-06-01 2009-07-29 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
KR20050044599A (ko) 2001-11-27 2005-05-12 와이어쓰 홀딩스 코포레이션 Egf-r 및 her2 키나아제의 억제제로서의3-시아노퀴놀린
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
WO2003103676A2 (en) 2002-06-05 2003-12-18 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
WO2004004644A2 (en) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
BRPI0413255A (pt) * 2003-08-01 2006-10-03 Wyeth Corp uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
MXPA06001590A (es) 2003-08-19 2006-05-19 Wyeth Corp Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
AU2003304497B2 (en) 2003-09-15 2010-06-24 Wyeth Llc Substituted quinolines as protein tyrosine kinase enzyme inhibitors
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
CA2566823A1 (en) 2003-11-05 2005-05-19 Board Of Regents, The University Of Texas System Diagnostic and therapeutic methods and compositions involving pten and breast cancer
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
AR047988A1 (es) 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
CN104774931B (zh) 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
MX2007000944A (es) 2004-07-23 2007-04-13 Astrazeneca Ab Metodo para pronosticar la sensibilidad de un tumor a farmacos del receptor erbb.
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
TW200626610A (en) 2004-10-13 2006-08-01 Wyeth Corp Analogs of 17-hydroxywortmannin as PI3K inhibitors
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
WO2006081985A1 (en) * 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
SI1859793T1 (sl) 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
WO2006098978A1 (en) 2005-03-09 2006-09-21 Abbott Laboratories Diagnostics method for identifying candidate patients for the treatment with trastuzumab
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
KR20080002826A (ko) 2005-04-14 2008-01-04 와이어쓰 게피티니브 내성 환자에서의 표피 성장 인자 수용체(egfr) 키나제 억제제의 용도
US20110045459A1 (en) 2005-04-21 2011-02-24 Mischel Paul S Molecular determinants of EGFR kinase inhibitor response in glioblastoma
ATE460937T1 (de) 2005-04-28 2010-04-15 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
US20080193448A1 (en) * 2005-05-12 2008-08-14 Pfizer Inc. Combinations and Methods of Using an Indolinone Compound
BRPI0610147A2 (pt) 2005-05-25 2010-06-01 Wyeth Corp método para preparar e sintetizar 3-cianoquinolinas substituìdas e 4-amino-3-cianoquinolinas
WO2006127205A2 (en) 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
DE102005053679A1 (de) 2005-06-24 2006-12-28 Bayer Healthcare Ag Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
WO2007011619A2 (en) 2005-07-15 2007-01-25 Wyeth Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate
WO2007015569A1 (ja) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (de) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Testverfahren für die wirkung eines vaskularisierungsinhibitors
CA2624613A1 (en) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Method to predict or monitor the response of a patient to an erbb receptor drug
US20110052570A1 (en) 2005-10-26 2011-03-03 Children's Medical Center Corporation Method to prognose response to anti-egfr therapeutics
WO2007056117A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
DK1948180T3 (da) 2005-11-11 2013-05-27 Boehringer Ingelheim Int Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
CN101312737B (zh) 2005-11-24 2012-11-14 爱库里斯股份有限两合公司 副痘病毒与传统细胞毒性化疗剂联合作为治疗癌症的生化治疗
JP2007145745A (ja) * 2005-11-25 2007-06-14 Osaka Univ 変異型EGFR下流シグナルを抑制するSrcファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
CA2632213A1 (en) 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
WO2007095038A2 (en) 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
CA2644841C (en) * 2006-04-07 2013-07-16 Novartis Ag Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
TW200806282A (en) 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
TW200808728A (en) 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
EP2032989B2 (de) 2006-06-30 2015-10-28 Merck Sharp & Dohme Corp. Igfbp2-biomarker
ES2385613T3 (es) 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Método para tratar cánceres que portan mutaciones de EGFR
CA2664697A1 (en) 2006-09-28 2008-04-10 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair
US20090317456A1 (en) 2006-10-13 2009-12-24 Medigene Ag Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
WO2008076257A2 (en) 2006-12-13 2008-06-26 Schering Corporation Treating cancer with anti-igflr antibody 19d12 = sch 717454
NZ578329A (en) 2006-12-13 2012-05-25 Schering Corp Igf1r inhibitors for treating cancer
WO2008076143A1 (en) 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
JP5406039B2 (ja) 2006-12-21 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な5−シアノ−4−(ピロロ[2,3b]ピリジン−3−イル)−ピリミジン誘導体
CN101631536A (zh) 2007-01-12 2010-01-20 惠氏公司 片中片组合物
CN104013956B (zh) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
ES2639854T3 (es) 2007-02-01 2017-10-30 Takeda Pharmaceutical Company Limited Preparación de comprimidos sin causar problemas de fabricación de comprimidos
WO2008121467A2 (en) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
US8715665B2 (en) 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
CA2684265A1 (en) 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
ES2569215T3 (es) 2007-09-10 2016-05-09 Boston Biomedical, Inc. Un nuevo grupo de inhibidores de la ruta de Stat3 e inhibidores de la ruta de las células madre del cáncer
WO2009042613A1 (en) 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101918579A (zh) 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
JP2011502571A (ja) 2007-11-05 2011-01-27 ピュアテック ベンチャーズ 医薬化合物を投与するための方法、キット、および組成物
MX2010006854A (es) 2007-12-18 2010-09-09 Schering Corp Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2009105234A2 (en) 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
CA2716826C (en) 2008-02-25 2017-05-09 Prometheus Laboratories Inc. Drug selection for breast cancer therapy using antibody-based arrays
WO2009111073A2 (en) 2008-03-06 2009-09-11 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
EP2259797A2 (de) 2008-03-25 2010-12-15 Schering Corporation Verfahren zur behandlung oder verhinderung von kolorektalkrebs
EP2279267A4 (de) 2008-03-27 2012-01-18 Vascular Biosciences Inc Verfahren zur identifizierung neuer therapiekandidaten über genexpressionsanalyse bei krankheiten in verbindung mit gefässen
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20110182888A1 (en) 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
JP5564490B2 (ja) 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
WO2009129545A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
NZ588710A (en) 2008-04-18 2012-12-21 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
CN104250280A (zh) 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
MX2010012064A (es) 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
KR20180128078A (ko) 2008-06-17 2018-11-30 와이어쓰 엘엘씨 Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물
JP5758801B2 (ja) 2008-07-22 2015-08-05 トラスティーズ・オブ・ダートマス・カレッジTrustees of Dartmouth College 単環式シアノエノンおよびその使用方法説明
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
US20100069340A1 (en) 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
EP3075864A1 (de) 2008-10-14 2016-10-05 Caris MPI, Inc. Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signatursets nach tumortyp
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
CN102223886A (zh) 2008-11-07 2011-10-19 安龙制药公司 Erbb-3(her3)选择性组合疗法
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
AU2010210636A1 (en) 2009-02-04 2011-09-22 Bipar Sciences, Inc. Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
WO2010098627A2 (ko) 2009-02-27 2010-09-02 한올바이오파마주식회사 약제학적 제제
US9073916B2 (en) 2009-03-11 2015-07-07 Auckland Uniservices Limited Prodrug forms of kinase inhibitors and their use in therapy
HUE061640T2 (hu) 2009-04-06 2023-07-28 Wyeth Llc Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
AR076053A1 (es) 2009-04-14 2011-05-18 Schering Corp Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
ES2659725T3 (es) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
CN102470109A (zh) 2009-07-02 2012-05-23 惠氏有限责任公司 3-氰基喹啉片剂制剂及其应用
KR20110007985A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 N,n―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
WO2011008053A2 (ko) 2009-07-17 2011-01-20 한올바이오파마주식회사 N,n-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
WO2011025269A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR20110021691A (ko) 2009-08-25 2011-03-04 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101211227B1 (ko) 2009-08-25 2012-12-11 한올바이오파마주식회사 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011038467A1 (en) 2009-10-01 2011-04-07 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia
CN107441058A (zh) 2009-11-09 2017-12-08 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
PT2498756T (pt) 2009-11-09 2019-11-26 Wyeth Llc Formulações de comprimidos de maleato de neratinib
EP2896632B1 (de) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material und Verfahren zur Behandlung oder Vorbeugung von HER-3-assoziierten Erkrankungen
US20130012465A1 (en) 2009-12-07 2013-01-10 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
EP2510121A1 (de) 2009-12-11 2012-10-17 Wyeth LLC Biomarker für phosphatidylinositol-3-kinase-signalweg
US8338456B2 (en) 2010-01-13 2012-12-25 Wyeth Llc Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor

Also Published As

Publication number Publication date
HK1218262A1 (zh) 2017-02-10
AU2009279771A1 (en) 2010-02-11
NZ590464A (en) 2012-10-26
EP2326329B1 (de) 2017-01-11
CN115990181A (zh) 2023-04-21
WO2010017163A1 (en) 2010-02-11
RU2011102797A (ru) 2012-09-10
US20100113474A1 (en) 2010-05-06
US9265784B2 (en) 2016-02-23
EP2326329A1 (de) 2011-06-01
ZA201101662B (en) 2011-11-30
IL210616A0 (en) 2011-03-31
BRPI0916694A2 (pt) 2015-11-17
PL3175853T3 (pl) 2024-03-25
AU2009279771B2 (en) 2015-05-14
CA2730715C (en) 2013-10-01
KR20140069340A (ko) 2014-06-09
EP4424375A2 (de) 2024-09-04
IL210616A (en) 2015-10-29
RU2498804C2 (ru) 2013-11-20
ES2968373T3 (es) 2024-05-09
BRPI0916694B1 (pt) 2021-06-08
CN109464445A (zh) 2019-03-15
CN113209121A (zh) 2021-08-06
ES2614912T3 (es) 2017-06-02
CY1118602T1 (el) 2017-07-12
SG10202102855RA (en) 2021-05-28
SMT201700084B (it) 2017-03-08
PT2326329T (pt) 2017-02-14
HUE032958T2 (hu) 2017-11-28
KR20110036604A (ko) 2011-04-07
US20140171384A1 (en) 2014-06-19
HRP20170074T1 (hr) 2017-03-24
PL2326329T3 (pl) 2017-07-31
KR101434009B1 (ko) 2014-08-25
CN105963313A (zh) 2016-09-28
JP2011529968A (ja) 2011-12-15
CN102202667A (zh) 2011-09-28
LT2326329T (lt) 2017-05-25
CA2730715A1 (en) 2010-02-11
JP5681108B2 (ja) 2015-03-04
EP3175853B1 (de) 2023-11-01
MX2011001318A (es) 2011-03-04
DK2326329T3 (en) 2017-02-20
CN105147713A (zh) 2015-12-16
SI2326329T1 (sl) 2017-06-30
US8669273B2 (en) 2014-03-11
EP3175853A1 (de) 2017-06-07

Similar Documents

Publication Publication Date Title
HK1218262A1 (zh) -苯胺基- -氰基喹啉和卡培他濱的抗腫瘤組合
HK1254895A1 (zh) 苄基苯衍生物及使用方法
EG27167A (en) Microemulsifiers and methods of making and using same
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
IL210153A0 (en) Nutrigenomics methods and compositions
ZA201109034B (en) Aminopyrrolidinone derivatives and uses thereof
IL212822A0 (en) Anti-cxcr1 compositions and methods
IL213974A0 (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives
GB0819530D0 (en) Methods and compositions
IL208771A0 (en) Iminopyridine derivatives and use thereof
HK1161720A1 (en) Dihydroetorphines and their preparation
EP2370414A4 (de) Herstellung von capecitabin
ZA201005482B (en) New macrolides and their use
IL206951A0 (en) 3-alkyl-piperazine derivatives and uses thereof
EP2274294A4 (de) 5-demethoxyfumagillol und derivate davon
GB0813359D0 (en) Halfin and/or platerfin
GB0811250D0 (en) Methods and compositions
IL206950A0 (en) Aminopiperidinyl derivatives and uses thereof
PL383161A1 (pl) N-N-dialkilowe pochodne 2-amino-2-deoksy-D- glukitolo-6- fosforanu i sposób ich otrzymywania
GB0816534D0 (en) Compositions and methods